Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + pyrotinib + dalpiciclib versus trastuzumab + pertuzumab + chemotherapy for neoadjuvant treatment of HER2-positive HR-negative early breast cancer
ChiCTR2500097681Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trastuzumab, pyrotinib, dalpiciclib and pertuzumab in breast cancer (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Pathological complete response. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500097681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097681.